Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Apatinib for Patients With Heavily Pretreated, Metastatic Esophageal Cancer.

NCT02544737 is registered in ClinicalTrials.gov with Hangzhou Cancer Hospital as lead sponsor.

NCT NCT02544737
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02544737 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Apatinib for Patients With Heavily Pretreated, Metastatic Esophageal Cancer.
Lead sponsor
Hangzhou Cancer Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
September 30, 2015
Completion date
December 31, 2017
Enrollment
29 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

apatinib, esophageal cancer, metastatic esophageal cancer